A PHASE 3, NON-INFERIORITY RANDOMIZED CONTROLLED TRIAL WITH FEXUPRAZAN, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER VS. ESOMEPRAZOLE IN PATIENTS WITH EROSIVE ESOPHAGITIS
Gastroenterology(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
Gastroenterology(2020)